In The News
Test post after maintenance
Construction Test 7
Construction Test 6
Construction Test 5
Construction test article 2
Test – Racing Victoria planned agreement to ‘seriously breach’ competition laws, court hears
Construction test article 1
I’m afraid AI can’t do that: Law firms say smart tech uses limited
Holden dealers reject GM’s bleak alternate reality in class action
Lawyer’s defamation case fails serious harm test, judge finds

US pharmaceutical giant Merck Sharp & Dohme has taken a unit of Indian generic manufacturer Lupin to court for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Januvia and Janumet.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.
Related articles
Merck Sharp & Dohme slams Wyeth vaccine patent claims as ‘hearsay and speculation’
Allens 2019-02-06 2:44 pm By Miklos Bolza
Merck Sharp & Dohme attacks Wyeth’s ‘broad’ patent claims for Prevnar 13 vaccine
Allens 2018-12-03 2:44 pm By Miklos Bolza
Merck Sharp & Dohme loses key battle in trade mark case ahead of trial
Angela McDonald 2019-07-15 2:44 pm By Miklos Bolza
Wyeth loses privilege claim over Allens docs in Merck’s vaccine patent case
Allens 2019-10-01 2:44 pm By Miklos Bolza
Merck Sharpe & Dohme sues Lupin over Januvia patent
Healthcare 2020-09-07 2:44 pm By Cat Fredenburgh

For information on rights and reprints, contact subscriptions@lawyerly.com.au